Results about: innovation
«Spark», a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
The goal of «Spark» is to carry out the first preclinical stage of the development of a first-in-class drug that will prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia and other mental disorders, and to be able to start first-in-humans trials by 2016
The project, which has just won a 500,000 euro endorsement from the Ministry of Economy and Finance and FEDER funds through the “Retos-Colaboración” (Challenges-Collaboration) subprogram- will be developed by a consortium led by the biotech Iproteos -located at the Parc Cientific de Barcelona- and comprised by the company Ascil-Biopharm, IRB Barcelona, the Centre for Genomic Regulation and the University of the Basque Country
Currently there is no drug targetting the cognitive impairment associated with schizophrenia, the third most disabling disease even above paraplegia and blindness- according to the WHO and that affects about 24 million people worldwide. It is also the fifth disease with a higher annual cost to society, with more than 35,000 million euros cost only in the Europe Union
“Cafè amb la Recerca” (Research over a coffee), organised by the “Fundació Catalana per a la Recerca i la Innovació”, seeks to offer a meeting point in which research centres, companies, and investors can explore collaboration initiatives.
In the first session of this series, Joan J. Guinovart, director of the IRB Barcelona and Josep Samitier, director of the IBEC presented their research lines to eight managerial representatives from the business and investment sectors.
IRB Barcelona launches a Business Advisory Board (BAB) to speed up technology transfer.
The BAB comprises distinguished representatives from pharmaceutical companies, venture capital enterprises, and agents specialized in promoting agreements between the public and private sectors.
Appraisal of innovation issues by the BAB is expected to boost the set up of new spin-offs, patent licenses, and the establishment of stable collaboration agreements with pharmaceutical companies around the world.